Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

bitopertin

Roche Basel Switzerland

Roche eyes September FDA verdict for triple NSCLC therapy

Roche hot on the heels of Merck in first-line non-small cell lung cancer market

- PMLiVE

Morning brief: Gilead partners with Verily, Roche expands 4DMT partnership and more

A rapid round up of pharma, biotech and healthcare news

- PMLiVE

CHMP backs first-line use for AZ’s Tagrisso in lung cancer

AstraZeneca, Roche and Gilead among companies one step closer to approval

Roche Basel Switzerland

Ocrevus helps Roche stave off biosimilar threat

Its low price strategy for the CD20-targeting antibody is paying off

- PMLiVE

Morning brief: Roche raises outlook for 2018, ASCO abstracts revealed and more

A rapid round up of pharma, biotech and healthcare news

- PMLiVE

Sanofi appoints ex-Roche Reed as new R&D head

John Reed to take up post after leaving Roche last month

- PMLiVE

Merck’s Keytruda scores in frontline lung cancer yet again

Drug improved overall survival as a monotherapy, which rival BMS’ Opdivo was unable to show

- PMLiVE

First blood to Roche in Hemlibra patent fight with Shire

The new haemophilia drug does not infringe Baxalta’s patent, rules Tokyo court

Roche Basel Switzerland

Another Tecentriq win for Roche as Avastin combo boosts survival

The Swiss pharma group reported a 38% improvement in PFS in NSCLC patients

- PMLiVE

New data could put Roche’s Tecentriq first in squamous lung cancer

NSCLC patients on the drug saw a reduced risk of disease progression

- PMLiVE

Mundipharma adds breast cancer biosimilar to its portfolio with Celltrion deal

Will launch Herzuma in seven European countries including the UK and Germany

Biogen Idec building

Biogen pays $590m for Pfizer cognition drug

Early stage studies look positive for schizophrenia drug

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links